



Frequencies of TTN mutation in solid tumors




Supplemental Figure 1. Frequencies of TTN mutation in multiple solid tumors.

Bar plot shows the percentage of patients with mutated-*TTN* for each solid tumor type. Detailed information including tumor name and data source are labeled and ordered according to decreasing frequencies of *TTN* mutation. Tumor types that have been approved by the FDA for being treated with ICB immunotherapies are colored in blue.




Supplemental Figure 2. Clinical relevance of *TTN* mutation in clinical trials.

Validation analysis of cohorts with available information. Objective response, defined as complete response and partial response, and TMB were assessed based on *TTN* mutation status. Statistics based on two-tailed Mann-Whitney *U*-test.




Supplementary Figure 3. Pan-cancer survival analysis for TTN mutation status.

Disease-free survival (DFS) and overall survival (OS), with or without TTN mutation status, are shown for pan-cancer cohort. Kaplan-Meier survival plots, p -value of log-rank test are shown. Red line/dot, patients with mutated TTN; blue line/dot, wild type patients.



Supplementary Figure 4. Survival between TTN mutation status for lung adenocarcinoma, lung squamous cell cancer and melanoma. Disease-free survival (DFS) and overall survival (OS) between TTN mutation status were analyzed for pan-cancer cohort. Kaplan-Meier survival plots, *p*-value of log-rank test are shown. Red line/dot, patients with mutated TTN; blue line/dot, wild type patients.



Supplemental Figure 5. Survival analysis for selected patients in ICB-treated cohorts. Survival analysis for *TTN* mutation status was performed for selected patients. Kaplan-Meier survival plots, *p*-value of log-rank test, and hazard ratios with 95% confidence interval (CI) are shown.